Dianthus Therapeutics (DNTH) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Veradermics is the larger company by market cap ($5.04 billion vs $4.76 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | MANE |
|---|---|---|
| Share price | $84.55 | $119.52 |
| Market cap | $4.76B | $5.04B |
| 1-day change | -0.33% | -3.92% |
| YTD return | +105.17% | — |
| 1-year return | +103.98% | — |
| 5-year return | -12.80% | — |
| EPS (TTM) | $-4.08 | $-3.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | — |
| Revenue growth (YoY) | -67.35% | — |
| Net income (latest FY) | $-162.34M | $-70.00M |
| Operating margin | -8739.34% | — |
| Net margin | -7973.33% | — |
| 52-week high | $117.88 | $156.63 |
| 52-week low | $35.84 | $32.00 |
| Distance from 52-week high | -28.27% | -23.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +64.70% | +56.74% |
| Average volume | 848.96K | 738.22K |
| Shares outstanding | 56.31M | 42.20M |
| Employees | 92 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
DNTH vs MANE FAQ
Which is bigger, Dianthus Therapeutics or Veradermics?
Veradermics (MANE) is larger, with a market capitalization of $5.04B compared with $4.76B for Dianthus Therapeutics (DNTH).
Are Dianthus Therapeutics and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.